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Methods: Thirty-nine consecutive cases consulted for undetermined 
mediastinal lesions from July 2005 to August 2006 were enrolled. 
Linear echoendoscope and 22-gauge aspiration or 19-gauge Trucut 
needles were used. Final diagnoses were determined by EUS-FNA/CB 
cytology, biospy, surgical pathology, or clinical follow-ups.
Results: Indications for EUS-FNA/CB were for histologic sampling 
in 24 cases (including suspected lung cancer, 9; other malignancy, 6; 
granulomatous disease, 3; unknown lesion, 6) and for stage conﬁrma-
tion of 15 proven malignancies (lung cancer, 11; extra-pulmonary 
malignancy, 4). FNA/CB was performed by mean number of 3.6 passes 
with four minimal complications (fever, 3; pain, 1). Malignant pathol-
ogy was obtained in 12 cases (primary lung cancer, 7; unknown origin, 
4; lymphoma, 1), and nine were deﬁned as benign lesions (tuberculo-
sis, 3; sarcoidosis, 1; reactive lymph node, 4; inconclusive bacterial 
infection, 1). In staging of 16 patients with proven malignancy (nodal 
staging of lung cancer, 11; metastasis of extra-pulmonary malignancy, 
4; recurrence of breast cancer, 1), 14 cases were diagnostic (metastatic, 
7; reactive, 7). Only four specimens (10.3%) were inadequate. Eleven 
of 39 patients (28.2%) had history of tuberculosis (prior pulmonary 
history, 7; present clinical impression, 4). Of the seven, six underwent 
FNA/CB for nodal staging of lung cancer and proved to be diagnostic 
(metastatic, 2; reactive, 4). The diagnostic accuracy of EUS-FNA/CB 
was as follows: overall, 87.2% (34/39); malignancy-related, 92.9% 
(26/28); lung cancer-related, 88.9% (16/18); tuberculosis-related, 
90.9% (10/11). 
Conclusions: EUS-FNA/CB is an accurate diagnostic modality in 
tissue conﬁrmation of undetermined mediastinal lesions. In addition, 
it should be recognized as an indispensable procedure to deﬁne benign 
reactive mediastinal lymph nodes that are commonly encountered in 
highly prevalent area of pulmonary tuberculosis.
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Introduction: Fluoro-deoxyglucose positron emission tomography 
(PET) has a diagnostic and prognostic value in staging and surveillance 
of non-small cell lung cancer. Several studies have also demonstrated 
its potential in assessing biologic aggressiveness of the primary tumor.
Aims: To evaluate the role of PET for early intraluminal squamous cell 
cancer (ISCC). 
Methods: Patients with early ISCC detected by autoﬂuorescence bron-
choscopy (AF) and conﬁned within the airway wall deﬁned initially by 
high resolution CT at 1 mm (subsequently by multidetector CT at 0.75 
mm slices) underwent PET imaging. 
Results: Sixty current and former smokers (47 males) with median 
age 68 years (range, 62-74) were consecutively entered in this study. 
Twenty four patients had visible tumor margins measuring ≤ 1cm2 
whilst 36 had margins extending beyond the visibility of AFB. PET 
was positive in 23 patients (38%): 7 (7/24, 39%) patients with margin-
visible tumors and 17 (16/36, 44%) with margin-invisible tumors. Nine 
patients underwent surgery for margin-invisible cancers of which 6 
were PET positive. However, 4 of the resected PET positive cancers 
were found to be severe dysplasia in 3 and mild dysplasia in 1. Medi-
astinal staging of the 9 patients who underwent surgery revealed 1 true 
PET positive N1 and 5 true negative N0. Two patients had false PET 
positive lymph nodes which were adjacent to the primary tumors and 1 
had false negative N1 that measured 6mm on CT. No distant metastasis 
was observed. The remaining patients were surgically unﬁt and were 
treated with bronchoscopic therapy. Median follow up was 40 months 
(range, 21-72), 41 patients were alive and 19 deceased. Lung cancer 
related mortality was 13%. PET positive cancers did not result in worse 
survival difference, p= 0.46 (Fig 1). 
Conclusion: Our preliminary results indicated that PET was not useful 
for the evaluation and prognostication of patients with early ISCC con-
ﬁned within the bronchial wall. In fact, false-positive PET results led to 
unnecessary surgery in 4 patients. 
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Background: Non-small cell lung cancer (NSCLC) staging directs 
treatment choice and inﬂuences prognosis. The diagnostic performance 
of conventional FDG-PET scan in lymph node (LN) staging is too 
low to avoid invasive nodal staging. It remains unknown whether the 
diagnostic performance of integrated FDG-PET/CT for LN staging, and 
the calculation of Standard Uptake Values (SUV) could make invasive 
staging redundant.
Methods: We prospectively investigated the mediastinal and/or hilar 
LN in patients with proven NSCLC with an integrated FDG-PET/CT. 
Pathologic conﬁrmation of all suspicious LN was obtained. The diag-
nostic performance of the FDG-PET/CT fusion images and of the SUV 
calculation was measured to the stage the intrathoracic LN.
Results: 105 intrathoracic LN stations from 52 patients with NSCLC 
were characterized. The prevalence of LN malignancy was 36%. The 
sensitivity of integrated FDG-PET/CT to detect malignant LN was 84% 
and its speciﬁcity was 85% (Positive likelihood ratio 5.64, Negative 
likelihood ratio 0.19). SUVMAX, SUVMEAN and the ratio of SUV-
MAX/SUVLIVER values were all signiﬁcantly higher in malignant 
than in benign LN. The ROC area did not differ between these three 
